Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21579056 | 0.88 | ADRB3 (0.62) | ADRB3ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4395710 | 0.80 | LMNA (0.48) | ADRB3 | |
| SCHEMBL2546108 | 0.77 | ADRB3 (0.64) | ADRB3ADRA2AADRA2BADRA2CADRA1A | |
| Hydrochloric Acid SCHEMBL11747192 | 0.77 | ADRB3 (0.57) | ADRB3ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4395904 | 0.75 | ALOX5 (0.53) | — | |
| SCHEMBL4884668 | 0.75 | ADRB3 (0.79) | ADRB3 | |
| SCHEMBL15894590 | 0.73 | ADRB3 (0.58) | ADRB3ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL966589 | 0.73 | ADRB3 (0.58) | ADRB3ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4398994 | 0.73 | KDM4E (0.47) | ADRB3 | |
| SCHEMBL4393587 | 0.72 | KDM4E (0.46) | ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188150-B2 | Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain | BIOCOPEA LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | OPRL1, HRH3, NR1H2 | ADRB3 12/4885ADRA2A 29/4885ADRA2B 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.